[go: up one dir, main page]

WO2005110460A3 - Diagnosis and treatment methods related to aging, especially in muscle (14.1) - Google Patents

Diagnosis and treatment methods related to aging, especially in muscle (14.1) Download PDF

Info

Publication number
WO2005110460A3
WO2005110460A3 PCT/US2005/014441 US2005014441W WO2005110460A3 WO 2005110460 A3 WO2005110460 A3 WO 2005110460A3 US 2005014441 W US2005014441 W US 2005014441W WO 2005110460 A3 WO2005110460 A3 WO 2005110460A3
Authority
WO
WIPO (PCT)
Prior art keywords
aging
muscle
diagnosis
treatment methods
methods related
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/014441
Other languages
French (fr)
Other versions
WO2005110460A2 (en
Inventor
John J Kopchick
Karen T Coschigano
Keith S Boyce
Andres Kriete
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio University
Cogenics Icoria Inc
Original Assignee
Ohio University
Icoria Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio University, Icoria Inc filed Critical Ohio University
Publication of WO2005110460A2 publication Critical patent/WO2005110460A2/en
Publication of WO2005110460A3 publication Critical patent/WO2005110460A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Mouse genes differentially expressed in comparisons of gene expression in different ages of mouse muscles have been identified, as have corresponding human genes and proteins. The human molecules, or antagonists thereof, may be used for protection against faster-than-normal biological aging, or to achieve slower-than-normal biological aging. The human molecules may also be used as markers of biological aging.
PCT/US2005/014441 2004-04-29 2005-04-28 Diagnosis and treatment methods related to aging, especially in muscle (14.1) Ceased WO2005110460A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56606804P 2004-04-29 2004-04-29
US60/566,068 2004-04-29
US57793004P 2004-06-09 2004-06-09
US60/577,930 2004-06-09

Publications (2)

Publication Number Publication Date
WO2005110460A2 WO2005110460A2 (en) 2005-11-24
WO2005110460A3 true WO2005110460A3 (en) 2006-04-13

Family

ID=34969798

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/014441 Ceased WO2005110460A2 (en) 2004-04-29 2005-04-28 Diagnosis and treatment methods related to aging, especially in muscle (14.1)

Country Status (1)

Country Link
WO (1) WO2005110460A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109540890A (en) * 2018-11-27 2019-03-29 湖南品胜生物技术有限公司 A kind of DNA quantitative analysis method based on microcytoscope image

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512401D0 (en) * 2005-06-17 2005-07-27 Randox Lab Ltd Method
US20200141948A1 (en) * 2017-06-21 2020-05-07 Korea Research Institute Of Bioscience And Biotechnology Method and kit for diagnosis of muscle weakness-related diseases using blood biomarker
CN113667739B (en) * 2021-08-27 2023-12-26 河北医科大学第二医院 Diagnostic marker combinations for coronary artery disease
EP4450970A1 (en) * 2023-04-19 2024-10-23 Startquake S.L. Aging clock markers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074911A2 (en) * 2001-03-19 2002-09-26 Wisconsin Alumni Research Foundation Identification of gene expression alterations underlying the aging process in mammals
WO2003025122A2 (en) * 2001-08-13 2003-03-27 University Of Kentucky Research Foundation Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074911A2 (en) * 2001-03-19 2002-09-26 Wisconsin Alumni Research Foundation Identification of gene expression alterations underlying the aging process in mammals
WO2003025122A2 (en) * 2001-08-13 2003-03-27 University Of Kentucky Research Foundation Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BODYAK NATALYA ET AL: "Gene expression profiling of the aging mouse cardiac myocytes", NUCLEIC ACIDS RESEARCH, vol. 30, no. 17, 1 September 2002 (2002-09-01), pages 3788 - 3794, XP002341760, ISSN: 0305-1048 *
BRONIKOWSKI A M ET AL: "Lifelong voluntary exercise in the mouse prevents age-related alterations in gene expression in the heart.", PHYSIOLOGICAL GENOMICS. 15 JAN 2003, vol. 12, no. 2, 15 January 2003 (2003-01-15), pages 129 - 138, XP002341762, ISSN: 1531-2267 *
LEE CHEOL-KOO ET AL: "Gene expression profile of aging and its retardation by caloric restriction", SCIENCE (WASHINGTON D C), vol. 285, no. 5432, 27 August 1999 (1999-08-27), pages 1390 - 1393, XP002341761, ISSN: 0036-8075 *
WEINDRUCH R ET AL: "Gene expression profiling of aging using DNA microarrays", MECHANISMS OF AGEING AND DEVELOPMENT, ELSEVIER SEQUOIA, LAUSANNE,, CH, vol. 123, 2002, pages 177 - 193, XP002304151, ISSN: 0047-6374 *
WEINDRUCH R ET AL: "Microarray profiling of gene expression in aging and its alteration by caloric restriction in mice", JOURNAL OF NUTRITION, WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, PHILADELPHIA, PA,, US, vol. 131, no. 3, March 2001 (2001-03-01), pages 918S - 923S, XP002961487, ISSN: 0022-3166 *
WELLE S ET AL: "Gene expression profile of aging in human muscle", PHYSIOLOGICAL GENOMICS 2003 UNITED STATES, vol. 14, 2003, pages 149 - 159, XP002341763, ISSN: 1531-2267 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109540890A (en) * 2018-11-27 2019-03-29 湖南品胜生物技术有限公司 A kind of DNA quantitative analysis method based on microcytoscope image

Also Published As

Publication number Publication date
WO2005110460A2 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
WO2006035237A3 (en) Methods and compositions relating to alzheimer's disease
WO2004076639A8 (en) Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus
WO2004092405A3 (en) Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
WO2006067122A3 (en) Binding molecules capable of neutralizing west nile virus and uses thereof
WO2008060813A3 (en) High affinity antibody antagonists of interleukin-13 receptor alpha 1
BRPI0511479A (en) binding molecule having rabies virus neutralizing activity, functional variant of a binding molecule, immunoconjugate, nucleic acid molecule, vector, host, method for producing a binding molecule or a functional variant, pharmaceutical composition, use of a binding, a functional variant, an immunoconjugate such as, or a composition, kit, method for identifying a binding molecule or a nucleic acid molecule, and collecting human binding molecules on the surface of replicable gene packages
WO2008042231A3 (en) Compositions and methods for evaluating and treating heart failure
WO2007143090A3 (en) Hepatocyte growth factor (hgf) binding proteins
WO2008039566A3 (en) Drugs and uses
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2006124892A3 (en) Modulators of alpha-synuclein toxicity
WO2005000335A3 (en) Use of genes differentially expressed during aging of liver for treatment and diagnosis
WO2009106819A3 (en) Biological materials and uses thereof
WO2004087965A3 (en) Statistical analysis of regulatory factor binding sites of differentially expressed genes
WO2008049098A3 (en) ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR α1
WO2005110460A3 (en) Diagnosis and treatment methods related to aging, especially in muscle (14.1)
WO2003076610A3 (en) Variants of human kallikrein-2 and kallikrein-3 and uses thereof
WO2004085614A3 (en) Nucleic acid molecules that are differentially regulated in a bipolar disorder and uses thereof
WO2009016231A3 (en) Compositions and methods for detecting histamine related disorders
EP2116616A3 (en) Genes differentially expressed in activated T cells and uses thereof
WO2005082398A3 (en) Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in muscle cells
WO2009021235A3 (en) Methods and compositions for treating cancer
WO2006122971A3 (en) Treatment of disease using an improved regulated expression system
WO2004089982A3 (en) April variants and methods thereof
WO2008126517A1 (en) Novel slc17-type transporter protein in mammal and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase